Evaluating Impurities in Drugs (Part II of III) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Impurities in Drugs (Part II of III)
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 58-72

References

1. FDA, Guidance for Industry—ANDAs: Impurities in Drug Products (Rockville, MD, Aug. 2005).

2. FDA, Guidance for Industry—ANDAs: Impurities in Drug Substances (Rockville, MD, Jan. 2005).

3. S. Görög, Identification and Determination of Impurities in Drugs (Elsevier Science, Amsterdam, 2000).

4. S. Ahuja, Impurities Evaluation of Pharmaceuticals (Marcel Dekker, New York, 1998).

5. S. Hovorka and C. Schöneich, J. Pharm.Sci. 90 (3), 253–269 (2001).

6. J. Roy, AAAPS PharmSciTech 3 (2), 1–8 (2002).

7. ICH, Q3A(R) Impurities in New Drug Substances (Feb. 2003).

8. ICH, Q3B(R) Impurities in Drug Products (Nov. 2003).

9. ICH, Q3C (R5) Impurities: Guideline for Residual Solvents (March 2011).

10. ICH, Q1A(R2) Stability Testing of New Drug Substances and Products (Nov. 2003).

11. K. R. Wadekar et al., Pharm. Technol. 36 (2), 46–51 (2012).

12. B.C. Allen, K.S Crump, and A.M. Shipp, Risk Anal.8 (4), 531–544 (1988).

13. S.W. Baertschi and D.W. Reynolds, "Introduction" in Pharmaceutical Stress Testing: Predicting Drug Degradation, J. Swarbick, Ed. (Taylor & Francis, New York, 2005), pp. 4–8.

14. S. Ahuja, Chiral Separations by Chromatography (Oxford University Press, New York, 2000).

15. S. Ahuja, Chiral Separations by Liquid Chromatography, ACS Symposium Series 471 (American Chemical Society, Washington, DC, 1991).

16. J. Trofast et al., Chirality 3 (6), 443–450 (1991).

17. B. Waldeck, Chirality 5 (5) 350–355 (1993).

18. L. Gillespie et al., Circulation 25, 281–291 (1962).

19. H. Kubota et al., Chem. Pharm. Bull. 40, 1619–1622 (1992).

20. R.B. Carter, J. Pharmacol. Exp. Ther. 234 (2), 299–306 (1985).

21. Chiral Agonists of Histamine in Fornitier in Histamine Research (Oxford, 1985), pp.39-46.

22. M.E. Goldman et al., J. Mol. Pharmacol. 25 (1), 18–23 (1984).

23. W.M. Welch et al., J. Med. Chem. 27 (11), 1508–1515 (1984).

24. B.K. Koe et al., J. Pharmacol. Exp. Ther. 226 (3), 686–700 (1983).

25. T. de Boer et al., Chromatogr. 26 (2), 156–165 (2012).

26. TGA, Australian Public Assessment Report for Asenapine (Woden, Australia, April 2011).

27. S.G. Allenmark, Chromatographic Enantioseparation: Methods and Applications (Ellis Horwood, Chichester, 1991).

28. G. Gubitz, Chromatographia 30, 555–564 (1990).

29. D.E. Drayer, Clin. Pharmacol. Ther. 40 (2), 125–133 (1986).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here